ALVR - Allovir Inc

-

$undefined

N/A

(N/A)

Allovir Inc NASDAQ:ALVR AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viruses for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir’s technology and manufacturing process enables the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.

Location: 1100 Winter Street, MA, 02451, US | Website: www.allovir.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-27.9M

Cash

129.6M

Avg Qtr Burn

-30.23M

Short % of Float

18.33%

Insider Ownership

49.22%

Institutional Own.

41.77%

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Posoleucel Details
BK virus, Kidney transplantation

Phase 2

Update

Posoleucel Details
Epstein-Barr virus, Human herpesvirus 6, BK virus, Adenovirus, Cytomegalovirus

Failed

Discontinued

Posoleucel Details
Virus-associated hemorrhagic cystitis , Adenovirus

Failed

Discontinued

ALVR106 Details
Respiratory syncytial virus, Influenza, Human metapneumovirus, Parainfluenza virus

Failed

Discontinued

Failed

Discontinued